Literature DB >> 25774344

Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery.

Femi Philip1, Eugene Blackstone1, Samir R Kapadia1.   

Abstract

BACKGROUND: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
METHODS: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
RESULTS: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
CONCLUSIONS: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.

Entities:  

Keywords:  Statin; beta-blocker; coronary artery bypass grafting (CABG)

Year:  2015        PMID: 25774344      PMCID: PMC4329164          DOI: 10.3978/j.issn.2223-3652.2015.02.01

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  22 in total

1.  Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

Authors:  M J Domanski; C B Borkowf; L Campeau; G L Knatterud; C White; B Hoogwerf; Y Rosenberg; N L Geller
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).

Authors:  Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak
Journal:  Circulation       Date:  2004-10-05       Impact factor: 29.690

3.  Impact of statin use on outcomes after coronary artery bypass graft surgery.

Authors:  Alexander Kulik; M Alan Brookhart; Raisa Levin; Marc Ruel; Daniel H Solomon; Niteesh K Choudhry
Journal:  Circulation       Date:  2008-10-13       Impact factor: 29.690

4.  Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.

Authors:  Rajendra H Mehta; T Bruce Ferguson; Renato D Lopes; Gail E Hafley; Michael J Mack; Nicholas T Kouchoukos; C Michael Gibson; Robert A Harrington; Robert M Califf; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

5.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

6.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

7.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

8.  Lipid-lowering interventions in angiographic trials.

Authors:  J E Rossouw
Journal:  Am J Cardiol       Date:  1995-09-28       Impact factor: 2.778

9.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

10.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.

Authors:  S Yusuf; D Zucker; P Peduzzi; L D Fisher; T Takaro; J W Kennedy; K Davis; T Killip; E Passamani; R Norris
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

View more
  4 in total

1.  Significance of preoperative left ventricular ejection fraction in 5-year outcome after isolated CABG.

Authors:  Aida Fallahzadeh; Ali Sheikhy; Ali Ajam; Saeed Sadeghian; Mina Pashang; Mahmoud Shirzad; Jamshid Bagheri; Soheil Mansourian; Shahram Momtahen; Kaveh Hosseini
Journal:  J Cardiothorac Surg       Date:  2021-12-27       Impact factor: 1.637

2.  Hypertension control after an initial cardiac event among Medicare patients with diabetes mellitus: A multidisciplinary group practice observational study.

Authors:  Ashish Chaddha; Maureen A Smith; Mari Palta; Heather M Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-23       Impact factor: 3.738

3.  Case-Only Survival Analysis Reveals Unique Effects of Genotype, Sex, and Coronary Disease Severity on Survivorship.

Authors:  Jennifer R Dungan; Xuejun Qin; Benjamin D Horne; John F Carlquist; Abanish Singh; Melissa Hurdle; Elizabeth Grass; Carol Haynes; Simon G Gregory; Svati H Shah; Elizabeth R Hauser; William E Kraus
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

4.  Quinine induced simvastatin toxicity through cytochrome inhibition - a case report.

Authors:  Johannes M Just; Klaus Weckbecker; Katja S Just
Journal:  BMC Geriatr       Date:  2016-10-01       Impact factor: 3.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.